A Phase 3 interventional study of CagriSema and Semaglutide in Hypertension and Obesity, sponsored by Novo Nordisk A/S. Not yet recruiting at 212 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
This study is testing whether CagriSema is safe and works well in adults with high blood pressure and excess body weight. Participants will receive CagriSema, semaglutide, cagrilintide, or placebo, and treatment will be assigned by chance. CagriSema and cagrilintide are investigational medicines, while semaglutide is already available by prescription.
6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.
This study's planned enrollment of 1,408 is above the median of 100 across 4,575 interventional studies indexed under Hypertension.
Browse Hypertension studies →Novo Nordisk A/S is the lead sponsor of 1,404 studies on the registry; 101 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 100 (49%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For participants with Type 2 Diabetes (T2D)
The following inclusion criteria apply at screening in addition to the inclusion criteria listed above:
Exclusion Criteria:
For participants without T2D
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive CagriSema subcutaneously once weekly.
Drug: CagriSema
Participants will receive semaglutide subcutaneously once weekly.
Drug: Semaglutide
Participants will receive cagrilintide subcutaneously once weekly.
Drug: Cagrilintide
Participants will receive placebo subcutaneously once weekly.
Drug: Placebo
CagriSema will be administered subcutaneously.
Semaglutide will be administered subcutaneously.
Cagrilintide will be administered subcutaneously.
Placebo will be administered subcutaneously.
CagriSema versus Placebo : Change in in-office systolic blood pressure (SBP)
Measured in millimeters of mercury (mmHg).
Time frame: From baseline (week 0) to week 32
CagriSema versus Semaglutide and Cagrilintide : Change in in-office systolic blood pressure
Measured in mmHg.
Time frame: From baseline (week 0) to week 32
Change in Home blood pressure monitoring (HBPM) -based systolic blood pressure
Measured in mmHg.
Time frame: From baseline (week 0) to week 32
Number of participants who achieve a target goal of in-office systolic blood pressure lesser than or equal to (≤) 130 mmHg
Measured as Count of participants.
Time frame: At Week 32
Number of participants who achieve American College of Cardiology and the American Heart Association (ACC/AHA) guidelines based blood pressure targets lesser than (<) 130/80 mmHg
Measured as Count of participants.
Time frame: At Week 32
Change in body weight (%)
Measured in percentage (%).
Time frame: From baseline (week 0) to week 32
Change in body weight (Kg)
Measured in Kilograms (kg).
Time frame: From baseline (week 0) to week 32
Change in waist circumference
Measured in centimetre (cm).
Time frame: From baseline (week 0) to week 32
Change in ACC/AHA 10-year atherosclerotic cardiovascular disease (ASCVD) risk score
Measured in percentage of risk. ACC/AHA risk estimator calculates 10 year risk of ASCVD using a formula which includes age, sex, race, total cholesterol, high density lipoprotein (HDL) cholesterol, systolic blood pressure, blood pressure medication use, diabetes status, smoking status; minimum score 0, maximum score 100 where higher score indicates higher risk of 10-year risk of ASCVD.
Time frame: From baseline (week 0) to week 32
Ratio to baseline of lipids: Total cholesterol
Measured in Ratio.
Time frame: From baseline (week 0) to week 32
Ratio to baseline of lipids: HDL cholesterol
Measured in Ratio.
Time frame: From baseline (week 0) to week 32
Ratio to baseline of lipids: Low Density Lipoprotein (LDL) cholesterol
Measured in Ratio.
Time frame: From baseline (week 0) to week 32
Ratio to baseline of lipids: Very Low Density Lipoprotein (VLDL) cholesterol
Measured in Ratio.
Time frame: From baseline (week 0) to week 32
Ratio to baseline of lipids: Non-HDL cholesterol
Measured in Ratio.
Time frame: From baseline (week 0) to week 32
Ratio to baseline of lipids: Triglycerides
Measured in Ratio.
Time frame: From baseline (week 0) to week 32
Ratio to baseline of high-sensitivity C-reactive protein (hsCRP)
Measured in Ratio.
Time frame: From baseline (week 0) to week 32
Showing the first 100 of 212 sites across 19 countries. Choose a country and city above to see the rest.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cagrilintide